Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$0.44 USD
+0.01 (2.22%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $0.44 0.00 (0.39%) 6:44 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Dare Bioscience, Inc. [DARE]
Reports for Purchase
Showing records 81 - 100 ( 213 total )
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Busy 2Q Paves the Way for Dare?s Potential First Approval in 4Q; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
FDA Accepts NDA for DARE-BV1, and Sets PDUFA Date for December 7th
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
NICHD Collaboration for Ovaprene Phase 3 Expected to Provide Key Infrastructure and Cost Savings; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
New CRADA Agreement Should Offset Costs of Ovaprene Pivotal Phase 3 Study
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Dare Announces Another Milestone in Busy Summer with Receipt of Gates Foundation Grant to Develop LARC1
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Gates Foundation Grants Upto $49M for DARE-LARC1-Total Commitment ~$70M
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Dare Hits Major Milestone with Submission of NDA for BV1; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
NDA Submitted for DARE-BV1, Potential PDUFA in 2021, Launch in 1H2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
PK Data for DARE-HRT1 Validates Tech, Supporting Our PT Increase to $11
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Positive DARE-HR-1 Phase 1 Validates IVR Technology for Vaginal Hormone Delivery; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Hormone Replacement Therapy (HRT), Too
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J